From MIGS integration to remote monitoring and next-generation therapeutics, glaucoma specialists explore how new approaches ...
Two sustained-release procedural pharmaceuticals or drug-delivery options are available in the US: the bimatoprost ...
A new population-based study published in the journal of Advances in Therapy revealed that individuals diagnosed with ...
Please provide your email address to receive an email when new articles are posted on . Data supported the practice of using a size V stimulus when sensitivity is too low with size III. Size V had ...
Glaucoma therapies have come a long way, but pain points still remain, according to a speaker at the American Academy of ...
Diorasis Therapeutics, a Boston-based biotechnology company developing durable gene therapies for glaucoma and other ...
The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...
Q3 2025 Earnings Call October 29, 2025 4:30 PM EDTCompany ParticipantsChristopher Lewis - Vice President of Investor ...
Ellon has taken his South Sudanese blind soccer team a step closer to their dream of playing at the 2028 Paralympics in California. The 22-year-old striker is representing South Sudan’s “Bright Stars, ...
The Manila Times on MSN
South Sudan's blind football team dreams of Paralympic glory
Blind football uses a bell in the ball to direct players on the five-a-side teams, using the Spanish word "voy" ("I'm coming" ...
Among them, Lucentis® is the first anti-vascular endothelial growth factor (VEGF) drug approved for ophthalmic use in China, and has accumulated mature clinical application experience, providing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback